UNSPSC 51142019: Filantor or filenadol

This classification denotes an analgesic agent with the molecular formula C14H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YFT8T83CF9, chemically known as 4-morpholineethanol, beta-1,3-benzodioxol-5-yl-alpha-methyl-, (r*,s*)-(+-)- but generally known as filenadol, which bears US NIH Compound Identifier 71224. European Medicines Agency schedules Filenadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07626MIG. The term FILENADOL is an International Non-Proprietary Name.

FILENADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Filantor or filenadol bears US NLM identifiers UMLS ID C0381655 and NCI Concept Code C65683. SMILES: O1CCN(C(C(O)C)C2CC3OCOC3CC2)CC1.

UNSPSC 51142019 Filantor or filenadol, a Commodity code, does not reflect the actual work state and local governments are buying under this designation. The three recent opportunities posted under this code involve naloxone procurement, therapeutic pharmacy initiatives for direct-to-manufacturer prescription fulfillment, and generic multi-source pharmaceuticals and over-the-counter products — none of which align with the code's stated pharmaceutical name. The mismatch suggests either a data-entry error in the source material or a tagging misalignment in the procurement system. State and local bodies soliciting under this code are acquiring emergency-response medications and pharmacy benefit management services rather than the specific pharmaceutical indicated by the code number.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multi-state and local government networks (Minnesota Multistate Cooperative Purchasing Alliance). Geographic activity spans Florida, Texas, and the Upper Midwest, with cooperative purchasing extending to Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; Texas HHS's RFI on direct-to-manufacturer prescription programs posted April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, spanning multiple state and local facilities. The code shows limited relevant recent activity relative to its nominal scope, and vendors should verify code assignment before pursuing opportunities tagged under this designation.